Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 306

1.

Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model.

Meriwether D, Sulaiman D, Volpe C, Dorfman A, Grijalva V, Dorreh N, Solorzano-Vargas RS, Wang J, O'Connor E, Papesh J, Larauche M, Trost H, Palgunachari MN, Anantharamaiah GM, Herschman HR, Martin MG, Fogelman AM, Reddy ST.

J Clin Invest. 2019 Jun 11;130. pii: 123700. doi: 10.1172/JCI123700.

2.

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma.

Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR.

Cancer Res. 2019 May 15;79(10):2748-2760. doi: 10.1158/0008-5472.CAN-18-2799. Epub 2019 Mar 18.

3.

Development and Application of FASA, a Model for Quantifying Fatty Acid Metabolism Using Stable Isotope Labeling.

Argus JP, Wilks MQ, Zhou QD, Hsieh WY, Khialeeva E, Hoi XP, Bui V, Xu S, Yu AK, Wang ES, Herschman HR, Williams KJ, Bensinger SJ.

Cell Rep. 2018 Dec 4;25(10):2919-2934.e8. doi: 10.1016/j.celrep.2018.11.041.

4.

A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers.

Xu S, Catapang A, Braas D, Stiles L, Doh HM, Lee JT, Graeber TG, Damoiseaux R, Shirihai O, Herschman HR.

Cancer Metab. 2018 Jun 28;6:7. doi: 10.1186/s40170-018-0181-8. eCollection 2018.

5.

Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin.

Xu S, Catapang A, Doh HM, Bayley NA, Lee JT, Braas D, Graeber TG, Herschman HR.

J Nucl Med. 2018 Jun 7. pii: jnumed.118.212365. doi: 10.2967/jnumed.118.212365. [Epub ahead of print]

6.

Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARβ/δ-Dependent Vasodilator Pathway.

Kirkby NS, Sampaio W, Etelvino G, Alves DT, Anders KL, Temponi R, Shala F, Nair AS, Ahmetaj-Shala B, Jiao J, Herschman HR, Wang X, Wahli W, Santos RA, Mitchell JA.

Hypertension. 2018 Feb;71(2):297-305. doi: 10.1161/HYPERTENSIONAHA.117.09906. Epub 2018 Jan 2. Erratum in: Hypertension. 2018 Mar;71(3):e10.

7.

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.

Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG.

Nat Commun. 2017 Aug 14;8(1):241. doi: 10.1038/s41467-017-00221-3.

8.

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.

Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A.

Nat Commun. 2016 Aug 1;7:12348. doi: 10.1038/ncomms12348.

9.

[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4027-32. doi: 10.1073/pnas.1524212113. Epub 2016 Mar 28.

10.

Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-κB and NFAT transcriptional pathways.

Kirkby NS, Chan MV, Zaiss AK, Garcia-Vaz E, Jiao J, Berglund LM, Verdu EF, Ahmetaj-Shala B, Wallace JL, Herschman HR, Gomez MF, Mitchell JA.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):434-9. doi: 10.1073/pnas.1517642113. Epub 2015 Dec 28.

11.

Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.

Zaiss AK, Foley EM, Lawrence R, Schneider LS, Hoveida H, Secrest P, Catapang AB, Yamaguchi Y, Alemany R, Shayakhmetov DM, Esko JD, Herschman HR.

J Virol. 2015 Oct 21;90(1):412-20. doi: 10.1128/JVI.01939-15. Print 2016 Jan 1.

12.

A reporter mouse for optical imaging of inflammation in mdx muscles.

Martinez L, Ermolova NV, Ishikawa TO, Stout DB, Herschman HR, Spencer MJ.

Skelet Muscle. 2015 Apr 30;5:15. doi: 10.1186/s13395-015-0042-x. eCollection 2015.

13.

Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.

Roulis M, Nikolaou C, Kotsaki E, Kaffe E, Karagianni N, Koliaraki V, Salpea K, Ragoussis J, Aidinis V, Martini E, Becker C, Herschman HR, Vetrano S, Danese S, Kollias G.

Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):E4658-67. doi: 10.1073/pnas.1415762111. Epub 2014 Oct 14.

14.

Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.

Vadivel K, Ponnuraj SM, Kumar Y, Zaiss AK, Bunce MW, Camire RM, Wu L, Evseenko D, Herschman HR, Bajaj MS, Bajaj SP.

J Biol Chem. 2014 Nov 7;289(45):31647-61. doi: 10.1074/jbc.M114.569665. Epub 2014 Sep 28.

15.

Deletion of prostaglandin E2 synthesizing enzymes in brain endothelial cells attenuates inflammatory fever.

Wilhelms DB, Kirilov M, Mirrasekhian E, Eskilsson A, Kugelberg UÖ, Klar C, Ridder DA, Herschman HR, Schwaninger M, Blomqvist A, Engblom D.

J Neurosci. 2014 Aug 27;34(35):11684-90. doi: 10.1523/JNEUROSCI.1838-14.2014.

16.

Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer.

Jiao J, Ishikawa TO, Dumlao DS, Norris PC, Magyar CE, Mikulec C, Catapang A, Dennis EA, Fischer SM, Herschman HR.

Mol Cancer Res. 2014 Nov;12(11):1677-88. doi: 10.1158/1541-7786.MCR-14-0397-T. Epub 2014 Jul 25.

17.

Reversible suppression of cyclooxygenase 2 (COX-2) expression in vivo by inducible RNA interference.

Zaiss AK, Zuber J, Chu C, Machado HB, Jiao J, Catapang AB, Ishikawa TO, Gil JS, Lowe SW, Herschman HR.

PLoS One. 2014 Jul 2;9(7):e101263. doi: 10.1371/journal.pone.0101263. eCollection 2014.

18.

The spatiotemporal role of COX-2 in osteogenic and chondrogenic differentiation of periosteum-derived mesenchymal progenitors in fracture repair.

Huang C, Xue M, Chen H, Jiao J, Herschman HR, O'Keefe RJ, Zhang X.

PLoS One. 2014 Jul 2;9(7):e100079. doi: 10.1371/journal.pone.0100079. eCollection 2014.

19.

Hepatic ischemia and reperfusion injury in the absence of myeloid cell-derived COX-2 in mice.

Duarte S, Kato H, Kuriyama N, Suko K, Ishikawa TO, Busuttil RW, Herschman HR, Coito AJ.

PLoS One. 2014 May 12;9(5):e96913. doi: 10.1371/journal.pone.0096913. eCollection 2014.

20.

Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication.

Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG.

J Exp Med. 2014 Mar 10;211(3):473-86. doi: 10.1084/jem.20131738. Epub 2014 Feb 24.

21.

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A.

Mol Oncol. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. Epub 2013 Dec 1.

22.

Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice.

Cherukuri DP, Ishikawa TO, Chun P, Catapang A, Elashoff D, Grogan TR, Bugni J, Herschman HR.

Mol Oncol. 2014 Mar;8(2):169-77. doi: 10.1016/j.molonc.2013.10.009. Epub 2013 Nov 8.

23.

Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.

Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG.

J Med Chem. 2013 Sep 12;56(17):6696-708. doi: 10.1021/jm400457y. Epub 2013 Aug 15.

24.

LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression.

Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie LS, Warner TD, Nicolaou A, Herschman HR, Mitchell JA.

PLoS One. 2013 Jul 9;8(7):e69524. doi: 10.1371/journal.pone.0069524. Print 2013.

25.

Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies.

Kirkby NS, Zaiss AK, Wright WR, Jiao J, Chan MV, Warner TD, Herschman HR, Mitchell JA.

Biochem Biophys Res Commun. 2013 Aug 23;438(2):249-56. doi: 10.1016/j.bbrc.2013.07.006. Epub 2013 Jul 11.

26.

Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress.

Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG.

J Exp Med. 2012 Nov 19;209(12):2215-28. doi: 10.1084/jem.20121061. Epub 2012 Nov 12.

27.

Application of a rapid, simple, and accurate adenovirus-based method to compare PET reporter gene/PET reporter probe systems.

Gil JS, Machado HB, Campbell DO, McCracken M, Radu C, Witte ON, Herschman HR.

Mol Imaging Biol. 2013 Jun;15(3):273-81. doi: 10.1007/s11307-012-0596-5.

28.

Cell intrinsic role of COX-2 in pancreatic cancer development.

Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR, Wu H.

Mol Cancer Ther. 2012 Oct;11(10):2127-37. doi: 10.1158/1535-7163.MCT-12-0342. Epub 2012 Jul 10.

29.

Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling.

Li HJ, Reinhardt F, Herschman HR, Weinberg RA.

Cancer Discov. 2012 Sep;2(9):840-55. doi: 10.1158/2159-8290.CD-12-0101. Epub 2012 Jul 3.

30.

A spotlight from prostate cancer.

Herschman HR, Czernin J.

Cancer Discov. 2012 Apr;2(4):301-3. doi: 10.1158/2159-8290.CD-12-0067.

31.
32.

Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate.

Zaiss AK, Lawrence R, Elashoff D, Esko JD, Herschman HR.

J Biol Chem. 2011 Jul 15;286(28):24535-43. doi: 10.1074/jbc.M111.241562. Epub 2011 May 19.

33.

Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis.

Ishikawa TO, Oshima M, Herschman HR.

Carcinogenesis. 2011 Mar;32(3):417-26. doi: 10.1093/carcin/bgq268. Epub 2010 Dec 14.

34.

Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells.

Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, Herschman HR, Cacalano N, Pyle AD, Park NH, Jewett A.

PLoS One. 2010 Jul 16;5(7):e11590. doi: 10.1371/journal.pone.0011590.

35.

Cox-2 gene expression in chemically induced skin papillomas cannot predict subsequent tumor fate.

Ishikawa TO, Jain NK, Herschman HR.

Mol Oncol. 2010 Aug;4(4):347-56. doi: 10.1016/j.molonc.2010.06.004. Epub 2010 Jun 16.

36.

Conditional bicistronic Cre reporter line expressing both firefly luciferase and β-galactosidase.

Ishikawa TO, Herschman HR.

Mol Imaging Biol. 2011 Apr;13(2):284-92. doi: 10.1007/s11307-010-0333-x.

37.

Novel anti-inflammatory functions for endothelial and myeloid cyclooxygenase-2 in a new mouse model of Crohn's disease.

Watanabe J, Lin JA, Narasimha AJ, Shahbazian A, Ishikawa TO, Martin MG, Herschman HR, Reddy ST.

Am J Physiol Gastrointest Liver Physiol. 2010 Jun;298(6):G842-50. doi: 10.1152/ajpgi.00468.2009. Epub 2010 Mar 18.

38.

Positron emission tomography imaging of DMBA/TPA mouse skin multi-step tumorigenesis.

Ishikawa TO, Kumar IP, Machado HB, Wong KP, Kusewitt D, Huang SC, Fischer SM, Herschman HR.

Mol Oncol. 2010 Apr;4(2):119-25. doi: 10.1016/j.molonc.2010.01.005. Epub 2010 Feb 2.

39.

Requirement for deoxycytidine kinase in T and B lymphocyte development.

Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG.

Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5551-6. doi: 10.1073/pnas.0913900107. Epub 2009 Dec 31.

40.

Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression.

Ishikawa TO, Herschman HR.

Carcinogenesis. 2010 Apr;31(4):729-36. doi: 10.1093/carcin/bgq002. Epub 2010 Jan 8.

41.

Synaptotagmin IV determines the linear Ca2+ dependence of vesicle fusion at auditory ribbon synapses.

Johnson SL, Franz C, Kuhn S, Furness DN, Rüttiger L, Münkner S, Rivolta MN, Seward EP, Herschman HR, Engel J, Knipper M, Marcotti W.

Nat Neurosci. 2010 Jan;13(1):45-52. doi: 10.1038/nn.2456. Epub 2009 Dec 13.

42.

Target identification using drug affinity responsive target stability (DARTS).

Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, Wang J, Wu RP, Gomez F, Loo JA, Wohlschlegel JA, Vondriska TM, Pelletier J, Herschman HR, Clardy J, Clarke CF, Huang J.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21984-9. doi: 10.1073/pnas.0910040106. Epub 2009 Dec 7.

43.

Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice.

Narasimha AJ, Watanabe J, Ishikawa TO, Priceman SJ, Wu L, Herschman HR, Reddy ST.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):260-8. doi: 10.1161/ATVBAHA.109.198762. Epub 2009 Nov 19.

44.

Parathyroid hormone induction of cyclooxygenase-2 in murine osteoblasts: role of the calcium-calcineurin-NFAT pathway.

Huang H, Chikazu D, Voznesensky OS, Herschman HR, Kream BE, Drissi H, Pilbeam CC.

J Bone Miner Res. 2010 Apr;25(4):819-29. doi: 10.1359/jbmr.091019.

45.

The influence of innate and pre-existing immunity on adenovirus therapy.

Zaiss AK, Machado HB, Herschman HR.

J Cell Biochem. 2009 Nov 1;108(4):778-90. doi: 10.1002/jcb.22328. Review.

46.

Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism.

Ohashi K, Ouchi N, Sato K, Higuchi A, Ishikawa TO, Herschman HR, Kihara S, Walsh K.

Mol Cell Biol. 2009 Jul;29(13):3487-99. doi: 10.1128/MCB.00126-09. Epub 2009 Apr 27.

47.

Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.

Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2847-52. doi: 10.1073/pnas.0812890106. Epub 2009 Feb 5.

48.

Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.

Li HJ, Everts M, Yamamoto M, Curiel DT, Herschman HR.

Cancer Res. 2009 Jan 15;69(2):554-64. doi: 10.1158/0008-5472.CAN-08-3209.

49.

Feedback regulation of cyclooxygenase-2 transcription ex vivo and in vivo.

Ishikawa TO, Jain N, Herschman HR.

Biochem Biophys Res Commun. 2009 Jan 16;378(3):534-8. doi: 10.1016/j.bbrc.2008.11.099. Epub 2008 Dec 4.

50.

COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.

Jain NK, Ishikawa TO, Spigelman I, Herschman HR.

Prostaglandins Leukot Essent Fatty Acids. 2008 Dec;79(6):183-90. doi: 10.1016/j.plefa.2008.08.001. Epub 2008 Oct 1.

Supplemental Content

Loading ...
Support Center